Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00001126
Other study ID # DMID 97-023
Secondary ID
Status Completed
Phase Phase 1
First received January 17, 2000
Last updated August 26, 2010
Est. completion date November 2005

Study information

Verified date November 2005
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see what dose of the drug cidofovir is safe to treat laryngeal papillomatosis (warts in the throat which occur over and over) in children.

Laryngeal papillomatosis is caused by infection with a virus called human papillomavirus (HPV). At present, there is no approved drug to treat this infection. However, cidofovir is a drug effective against several viruses. Cidofovir may be able to attack the HPV virus. This study tests the safety of giving this drug to children.


Description:

Your child will be assigned randomly (like tossing a coin) to receive either cidofovir or placebo (an inactive substance). Neither you nor your doctor will know which your child is receiving. Your child will undergo a total of 6 bronchoscopic procedures, which involves placing a tube down your child's throat so that the warts can be seen and treated. The warts will be removed by laser or other procedures and the study drug injected. Study drug will be injected at the sites of all newly removed warts and warts which were removed during earlier study visits. This procedure will be performed every other week. Blood and urine tests will also be performed at this time. Your child will be under general anesthesia during each procedure and will be in the surgery unit for about 6 to 8 hours. Your child will also have to be seen by the doctor 2 days after the procedure. Your child will be followed for a total of 5 years to make sure he/she develops normally and to monitor any side effects of cidofovir. Follow-up visits will take place at Months 3, 6, and then once every 6 months through Year 5. If necessary, laser or other procedures will be performed at these visits to remove any warts.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date November 2005
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 2 Years to 17 Years
Eligibility Inclusion Criteria:

Your child may be eligible for this study if he/she:

- Has active laryngeal papillomatosis (warts in the throat) that requires 8 or more surgeries per year.

- Developed this infection before the age of 16.

- Is between the ages of 2 and 17 years with consent of parent or guardian.

Exclusion Criteria:

Your child will not be eligible for this study if he/she:

- Has a history of a prior malignancy (cancer), kidney disease, or immune system deficiency.

- Is HIV-positive.

- Is allergic to probenecid.

- Has received radiation therapy to the throat area or has received certain medications.

- Is pregnant or breast-feeding.

Study Design

Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Cidofovir


Locations

Country Name City State
United States NIAID/DMID/CASG Central Unit Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Terminated NCT01234480 - Intended Use Study of the BD SurePath Plus™ Pap
Terminated NCT00591305 - New Therapy of Laryngeal Papilloma In Children N/A
Completed NCT00038714 - A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis Phase 2
Completed NCT00006444 - The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women N/A
Withdrawn NCT01175499 - Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract N/A
Completed NCT05625308 - Effect of Natural Compounds on the Severity of HPV-induced Cervical Lesions N/A
Completed NCT01827423 - Squamous Cell Carcinoma Antigen Analysis at the University Hospital Ostrava N/A
Completed NCT00001603 - The Effects of Upper Airway and Digestive Tract Tumors on the Immune System N/A
Recruiting NCT05797246 - Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) Phase 2